Jenscare Scientific Co., Ltd. (Jenscare Scientific) announced that every item on the agenda of its 2025 Annual General Meeting, held on 28 May 2026 in Ningbo, Zhejiang Province, received shareholder approval by poll.

Attendance and voting base • Outstanding share capital eligible to vote: 417.17 million shares. • Shares represented in person or by proxy: 299.09 million, translating into a turnout of 71.70 %.

Key ordinary resolutions (100 % approval unless stated) 1. 2025 Board Report, consolidated financial statements and Annual Report. 2. 2025 profit distribution plan. 3. Re-appointment of Ernst & Young as external auditor for the 2026 financial year; the board is authorised to finalise remuneration and related terms. 4. Director remuneration for 2026—passed with 219.92 million votes in favour after 114.10 million shares abstained in line with concert-party obligations.

Special resolutions • General share-issuance mandate: 298.94 million votes (99.95 %) in favour, 148,600 votes (0.05 %) against. • H-share repurchase mandate: unanimous approval with 299.09 million votes (100 %).

Abstentions and compliance notes 114.10 million shares linked to concert-party participants and 354,000 H shares under the company’s share scheme abstained from voting on relevant items, in accordance with Hong Kong listing rules and internal governance agreements. No treasury shares existed, and no shareholder signalled an intention to oppose any proposal.

Vote-scrutiny assurance Computershare Hong Kong Investor Services Limited served as scrutineer, joined by shareholder representatives and counsel from Commerce & Finance Law Offices, validating the poll results.

With these approvals, Jenscare Scientific renews its audit relationship with Ernst & Young, maintains board compensation arrangements and gains flexibility to issue and repurchase H shares through newly authorised mandates.